Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on Longboard Pharmaceuticals (LBPH) and maintained a $60 price target.
March 13, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on Longboard Pharmaceuticals with a $60 price target.
The reiteration of an Overweight rating and a high price target of $60 by a reputable analyst suggests a strong bullish outlook for LBPH. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100